(NasdaqGM:RYTM), BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Hunter C. Smith, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 conference […]

(NASDAQ:ERAS), SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at

(NASDAQ:CABA), PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

LB Pharmaceuticals Announces $100.0 Million Private Placement GlobeNewswire February 05, 2026 NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced that it has entered into a securities purchase agreement

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 Conference call scheduled for 4:30 p.m. Eastern Time GlobeNewswire February 05, 2026 WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that

AdvanceIQ.ai Launches Risk & Portfolio Intelligence Platform for SMB Lending GlobeNewswire February 05, 2026 NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) — AdvanceIQ.ai, a leading provider of risk and portfolio intelligence for the SMB lending and private credit market, today announced the launch of the AIQ Platform, a unified intelligence platform supporting SMB lenders and

Playtika Announces Date of Fourth Quarter 2025 Results Conference Call GlobeNewswire February 05, 2026 HERZLIYA, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) — Playtika Holding Corp. (NASDAQ:PLTK) announced today that it will release financial results for the fourth quarter of 2025 before U.S. markets open on Thursday, February 26, 2026. On the same day, Playtika management

LM Funding America Announces January 2026 Production and Operational Update GlobeNewswire February 05, 2026 – Bitcoin treasury as of January 31, 2026 was 364.1 BTC valued at $29.1 million or $1.36 per share1 TAMPA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury

Accumulus Technologies Achieves SOC 2 Type 2 Attestation, HITRUST i1 Certification, and ISO 27001 Certification for the Accumulus Platform GlobeNewswire February 05, 2026 SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) — Accumulus Technologies, a leading cloud technology provider for regulatory exchange, today announced the achievement of three major third-party security milestones for the Accumulus platform

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 GlobeNewswire February 05, 2026 SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full